Inhibikase Therapeutics, Inc. (IKT): Net Income

Annual figures by period end, from SEC filings.

-$48.26M

Year ended 2025-12-31

-$60.64M

Trailing 12 months to 2026-06-30

2020-12-31 Net Income (USD) 2025-12-31

Period ended	Net Income	Change YoY	Source filing
2025-12-31	-$48.26M	n/m	2026-03-26, From 2025-01-01
2024-12-31	-$27.52M	n/m	2026-03-26, From 2024-01-01
2023-12-31	-$19.03M	n/m	2025-03-27, From 2023-01-01
2022-12-31	-$18.05M	n/m	2024-03-27, From 2022-01-01
2021-12-31	-$14.79M	n/m	2023-03-31, From 2021-01-01
2020-12-31	-$2.85M	n/a	2022-03-31, From 2020-01-01

Net Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Net Income	Change YoY
Inhibikase Therapeutics, Inc. (IKT)	2025-12-31	-$48.26M	n/m
Vaxart, Inc. (VXRT)	2025-12-31	$16.33M	n/m
Editas Medicine, Inc. (EDIT)	2025-12-31	-$160.06M	n/m
Caribou Biosciences, Inc. (CRBU)	2025-12-31	-$148.12M	n/m
Sutro Biopharma, Inc. (STRO)	2025-12-31	-$191.09M	n/m
SAB Biotherapeutics, Inc. (SABS)	2025-12-31	$13.27M	n/m
Neumora Therapeutics, Inc. (NMRA)	2025-12-31	-$236.93M	n/m
Aura Biosciences, Inc. (AURA)	2025-12-31	-$106.19M	n/m
Cabaletta Bio, Inc. (CABA)	2025-12-31	-$167.86M	n/m

Compare IKT, VXRT, EDIT, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗